Somatropin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome

Trial Timeline

Aug 1, 1999 → Aug 1, 2003

NCT ID

NCT00406926

About Somatropin

Somatropin is a phase 3 stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00406926. Target conditions include Turner Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00191360	Phase 3	Completed	Jan 1, 2003	May 1, 2006	Adult Growth Hormone Deficiency
NCT00191529	Phase 3	Completed	Dec 1, 2002	Jun 1, 2007	Infant, Small for Gestational Age
NCT00406926	Phase 3	Completed	Aug 1, 1999	Aug 1, 2003	Turner Syndrome
NCT00490191	Approved	Completed	Jan 1, 1999	Jul 1, 2001	Hypopituitarism

Competing Products

10 competing products in Turner Syndrome

See all competitors

Product	Company	Stage	Hype Score
Humatrope	Eli Lilly	Approved	85
17 beta estradiol	Eli Lilly	Phase 3	77
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate	Eli Lilly	Phase 3	77
r-hGH	Merck	Approved	85
Somapacitan + Norditropin®	Novo Nordisk	Phase 3	76
estradiol	Novo Nordisk	Approved	84
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch	Novo Nordisk	Phase 1	32
somatotropin	Pfizer	Pre-clinical	22
Lonapegsomatropin + Somatropin	Ascendis Pharma	Phase 2	49
Somatropin (rDNA origin)	Ipsen	Phase 3	74

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved